ADVFN - Advanced Financial Network.
HOME» NASDAQ » H » HGSI Stock Price » HGSI Stock News

Human Genome Sciences Share News

 Human Genome Sciences (mm) Stock Price
HGSI Stock Price
 Human Genome Sciences (mm) Stock Chart
HGSI Stock Chart
 Human Genome Sciences (mm) Stock News
HGSI Stock News
 Human Genome Sciences (mm) Company Information
HGSI Company Information
 Human Genome Sciences (mm) Stock Trades
HGSI Stock Trades

GlaxoSmithKline Confirms Rejected $13/Share Approach To Human Genome

LONDON -(Dow Jones)- GlaxoSmithKline PLC (GSK.LN) confirmed Thursday that it made an offer to the board of Human Genome Sciences (HGSI) on April 11 proposing to buy the outstanding shares of Human Genome for $13 each in cash, but said the offer has been rejected without discussion. MAIN FACTS: -GlaxoSmithKline believes the acquisition can be completed expeditiously and is prepared to start a cash tender offer with no financing or due diligence condition. -Offer represented a 81% premium to Human Genome's closing share price Wednesday. -Through complete ownership, GlaxoSmithKline can simplify and optimize R&D, commercial and manufacturing operations to advance these products most effectively and efficiently while securing the full potential long-term value of the assets. -GlaxoSmithKline expects to achieve at least $200 million in cost synergies to be fully realized by 2015 and expect the transaction to be earnings-accretive beginning in 2013. -GlaxoSmithKline has also assessed the potential returns of this acquisition relative to its long-term share buyback program. -As part of this ongoing program, GlaxoSmithKline continues to expect to repurchase GBP1 billion to 2 billion in shares in 2012. -GlaxoSmithKline shares at 1153 GMT up 17 pence or 1.1%, at GBP14.58, valuing the company at GBP72.69 billion. -By Razak Musah Baba, Dow Jones Newswires; 44-20-7842-9275; razak.baba@dowjones.com

Stock News for Human Genome Sciences (HGSI)
DateTimeHeadline
08/03/201203:00:56GlaxoSmithKline Completes Acquisition of Human Genome Sciences
07/30/201209:06:49GlaxoSmithKline Gets 79% Tenders for Human Genome Sciences Offer
07/15/201219:10:13Glaxo Eyes Human Genome Sciences for $2.6 Billion
07/15/201215:49:18Sources Say GlaxoSmithKline in Talks to Acquire Human Genome...
07/11/201212:36:14Glaxo To File Experimental Diabetes Drug Albiglutide In Early...
07/10/201208:38:08Human Genome: FDA Sets Dec. 15 Action Date For Anthrax Treatment...
07/03/201217:08:09GlaxoSmithKline Readies Candidates to Replace Human Genome's...
06/29/201209:24:03Glaxo Keeps Pressure On Human Genome By Extending Offer To July...
06/29/201207:35:49GlaxoSmithKline Sets July 20 For Expiration Of Tender Offer To...
06/15/201210:42:11GSK Gets Renewed Invitation to Human Genome Sciences Strategic...
06/08/201209:10:55GlaxoSmithKline Extends HGS Offer To June 29
06/07/201211:43:24Glaxo Seen Likely to Extend Hostile Tender Offer for Human Genome
05/30/201211:58:59GlaxoSmithKline Is Said To Plan Effort To Replace Human Genome...
05/23/201209:12:46Glaxo Amends Offer To Address HGS Shareholder Rights Plan
05/17/201217:45:35ADR Report: Shares Lower As Euro-Zone Worries Loom
05/17/201213:54:16GlaxoSmithKline Offer To Acquire HGS Represents Full, Fair Value
05/17/201207:55:44Human Genome Adopts Poison Pill With 15% Trigger To Deter Glaxo
05/09/201209:33:24WSJ BLOG/Health: A.M. Vitals: GSK's Hostile Human Genome Bid;...
05/09/201205:02:12Glaxo Goes Direct To HGS Shareholders With Hostile Offer
05/09/201202:48:24GlaxoSmithKline To Launch $13/Share Tender Offer For To Buy HGS

Human Genome Sciences and other NASDAQ stock quotes are delayed by at least 20 minutes.
All other stock price and quote data is delayed by at least 15 minutes unless otherwise stated. By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Contact Us | Copyright 1999-2007 ADVFN PLC. | Privacy Policy | Investment Warning | Data accreditations | Investor Relations

ADVFNADVFN ItalyADVFN GermanyADVFN FranceADVFN BrazilADVFN JapanADVFN UKADVFN US noad